Diet for Hypoglycemia - Postprandial Hypoglycemia News

Postprandial Hypoglycemia News

Halozyme presents new data from Ultrafast Insulin development program at 70th ADA Monday, June 28, 2010 @ 5:53AMHalozyme Therapeutics, Inc. today announced Phase 2 results demonstrating that the subcutaneous coinjection of rHuPH20 (recombinant human hyaluronidase, PH20) with lispro significantly improves postprandial hyperglycemia, reduces hypoglycemia, and accelerates the absorption of mealtime insulin in patients with type 2 diabetes.
Halozyme's Ultrafast Insulin Accelerates Absorption and Lowers Hyperglycemia and Hypoglycemia Risk in Type 2 Diabetes ... Sunday, June 27, 2010 @ 1:13PMSAN DIEGO, June 27 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
Halozyme's Ultrafast Insulin Accelerates Absorption and Lowers Hyperglycemia and Hypoglycemia Risk in Type 2 Diabetes ... Sunday, June 27, 2010 @ 11:00AMHalozyme Therapeutics, Inc. today announced Phase 2 results demonstrating that the subcutaneous coinjection of rHuPH20 with lispro significantly improves postprandial hyperglycemia, reduces hypoglycemia, and accelerates the absorption of mealtime insulin in patients with type 2 diabetes.
Studies Demonstrate Potential Benefits of More-Rapid-Acting Injectable Insulins: Poster Presentations at Annual ... Saturday, June 26, 2010 @ 1:30PMORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- Studies of a more-rapid-acting injectable human insulin formulation (VIAject®) in the treatment of type 1 and type 2 diabetes and of a novel insulin analog formulation (Vialog(TM)) in an animal model of diabetes were reported this week in three poster presentations at the 70th Scientific Sessions of the American Diabetes Association in Orlando ...
Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) Saturday, June 26, 2010 @ 9:00AMAmylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTAÂ® injection added to LantusÂ® , which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia.
Study Shows AFRESA® Provides Rapid Suppression of Endogenous Glucose Production in Diabetes Patients Tuesday, September 29, 2009 @ 10:30AMVIENNA----AFRESA® Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.
Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs Monday, September 28, 2009 @ 7:31AMHalozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics ...
Halozyme Begins Clinical Trial to Compare Three Insulin Analogs and Provides Update on Ultrafast Insulin Program Monday, September 28, 2009 @ 6:29AMSAN DIEGO----Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial insulin analogs administered with its proprietary rHuPH20 hyaluronidase enzyme compared to each of the analogs alone.
VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes Monday, June 8, 2009 @ 5:00PMYear-Long Phase 2 Diabetes Study Results Presented at ADA Annual Meeting -
International Diabetes Study Establishes GlycoMark as Definitive Test for Blood Sugar Swings in Seemingly ... Saturday, June 6, 2009 @ 10:00AMNEW ORLEANS----A team of researchers sponsored by three major international diabetes organizations has definitively established that the GlycoMark® test , a simple blood test used to measure glucose control in patients with diabetes, accurately reveals potentially dangerous fluctuations in blood sugar that are undetectable by other means.